Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib, an oral Janus kinase (JAK) inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis not previously treated with a JAK inhibitor, according to a presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1


Read more

Posted in Uncategorized.

Leave a Reply

Your email address will not be published. Required fields are marked *